

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

GEACH

Serial No. 10/537,047

Filed: June 2, 2005



Atty. Ref.: 613-96

TC/A.U.:

Examiner:

For: PREPARATION COMPRISING 1,3 AND/OR 1,6 BETA GLUCANS  
FOR THE TREATMENT OF INFECTIONS AND INFLAMMATIONS IN  
ANIMALS

\* \* \* \* \*

September 6, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. § 1.55 and in conformance with the procedures of 37 C.F.R. § 1.98, applicant hereby brings the documents listed on the attached modified PTO Form No. PTO/SB/08a to the attention of the examiner. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that each document be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of the non-U.S. patent, publication or other information listed on the modified PTO form PTO/SB/08a is enclosed.

Please return to the undersigned a copy of the attached PTO/SB/08A with the examiner's initials in the left column [MPEP § 609] with the next communication.

The Commissioner is hereby authorized to charge our Deposit Account No. 14-1140 for any fees required in connection with the filing of this Information Disclosure Statement. In particular, in the event that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is authorized to charge the above-named deposit account for any fees required pursuant to C.F.R. §§ 1.17(p) or 1.17(i)(1).


GEACH

Serial No. 10/537,047

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Arthur R. Crawford

Reg. No. 25,327

ARC:eaw

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

613-96

APPLICANT

GEACH

FILING DATE

June 2, 2005

SERIAL NO.

10/537,047

TC/A.U.

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,702,719	12/1997	Donzis			
	6,214,337 B1	4/2001	Hayen et al			
	6,303,175 B1	10/2001	Kurzinger et al			
	6,783,778 B1	8/2004	Schmidt et al			
	5,719,189	2/1998	Schmidt et al			
	5,401,727	3/1995	Rorstad et al			
	6,369,216 B1	4/2002	Patchen et al			
	2002/0082418 A1	6/2002	Ikewaki et al			
	6,306,453 B1	10/2001	Kurzinger			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 00/76329 A1	12/2000	PCT			
WO 97/08960	3/1997	PCT			
02218615	8/1990	Japan			ABSTRACT
WO 95/04467	2/1995	PCT			
0 466 037 A2	1/1992	EP			
WO 00/54741	9/2000	PCT			
WO 95/30022	11/1995	PCT			
WO 00/18411	4/2000	PCT			
0 875 244 A3	11/1998	EP			
1 393 734 A1	3/2004	EP			
WO 02/41900 A1	5/2002	PCT			
WO 96/28476	9/1996	PCT			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Derwent WPI Section Ch, Week 200169; XP002269872 and JP 2001 190231 A, 17 July 2001.
	Figueras et al; "Influence of the Sequence of Administration of Beta-Glucans ...", Veterinary Immunology and Immunopathology, Amsterdam, NL, Vol. 64, 1998, pages 59-68, XP002924640.
	Bohn et al, "(1→3)-β-D-Glucans as biological ...", Carbohydrate Polymers 28 (1995) 3-14.
	Siwicki et al, "Dietary intake of immunostimulants by rainbow ...", Veterinary Immunology and Immunopathology, 41 (1994) 125-139.
	Hetland et al, "β-1,3-Glucan reduces growth ...", FEMS Immunology and Medical Microbiology 33 (2002) 41-45.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.